(RGNX) Regenxbio - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75901B1070

Stock: Gene Therapy, Drug Candidates, Technology Platform

Total Rating 32
Risk 42
Buy Signal -0.43
Biotechnology +4.9
Biotechnology +3.0
Market Cap: 458m
Avg Trading Vol: 8.04M USD
ATR: 8.98%
Peers RS (IBD): 15.5
Risk 5d forecast
Volatility 76.4%
Relative Tail Risk -5.51%
Reward TTM
Sharpe Ratio 0.77
Alpha 16.45
Character TTM
Beta 1.737
Beta Downside 0.687
Drawdowns 3y
Max DD 78.42%
CAGR/Max DD -0.34

EPS (Earnings per Share)

EPS (Earnings per Share) of RGNX over the last years for every Quarter: "2021-03": -1.2, "2021-06": -1.36, "2021-09": -1.37, "2021-12": 6.67, "2022-03": -1.79, "2022-06": -1.58, "2022-09": -1.75, "2022-12": -1.38, "2023-03": -1.53, "2023-06": -1.66, "2023-09": -1.41, "2023-12": -1.43, "2024-03": -1.33, "2024-06": -1.05, "2024-09": -1.17, "2024-12": -1.01, "2025-03": 0.12, "2025-06": -1.38, "2025-09": -1.2, "2025-12": 0,
EPS CAGR: 102.02%
EPS Trend: 66.7%
Last SUE: 3.14
Qual. Beats: 1

Revenue

Revenue of RGNX over the last years for every Quarter: 2021-03: 18.884, 2021-06: 22.035, 2021-09: 30.773, 2021-12: 398.655, 2022-03: 22.218, 2022-06: 32.649, 2022-09: 26.512, 2022-12: 31.345, 2023-03: 19.138, 2023-06: 19.977, 2023-09: 28.914, 2023-12: 22.213, 2024-03: 15.622, 2024-06: 22.295, 2024-09: 24.197, 2024-12: 21.214, 2025-03: 89.012, 2025-06: 21.359, 2025-09: 29.733, 2025-12: null,
Rev. CAGR: -49.95%
Rev. Trend: -26.7%
Last SUE: 0.66
Qual. Beats: 0

Description: RGNX Regenxbio March 05, 2026

REGENXBIO Inc. (RGNX) is a clinical-stage biotechnology company developing gene therapies in the United States. The companys therapies aim to correct genetic defects by delivering functional genes to cells, a common approach in gene therapy.

RGNX utilizes its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system. AAV vectors are frequently used in gene therapy due to their safety profile and ability to infect both dividing and non-dividing cells.

Key pipeline candidates include ABBV-RGX-314 for various retinal diseases and RGX-202, currently in Phase III for Duchenne muscular dystrophy. The company also develops treatments for mucopolysaccharidosis types I and II, and neuronal ceroid lipofuscinosis type 2.

RGNX licenses its NAV Technology Platform to other companies, indicating a dual business model of internal drug development and technology commercialization. A collaboration with AbbVie Global Enterprises Ltd. extends the development of ABBV-RGX-314 internationally. To gain deeper insights into RGNXs market position and financials, further research on ValueRay is recommended.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -177.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.20 > 0.02 and ΔFCF/TA 15.35 > 1.0
NWC/Revenue: 128.6% < 20% (prev 249.8%; Δ -121.3% < -1%)
CFO/TA -0.20 > 3% & CFO -103.3m > Net Income -177.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.66 > 1.5 & < 3
Outstanding Shares: last quarter (51.7m) vs 12m ago 1.75% < -2%
Gross Margin: 49.98% > 18% (prev 0.39%; Δ 4958 % > 0.5%)
Asset Turnover: 30.89% > 50% (prev 16.24%; Δ 14.65% > 0%)
Interest Coverage Ratio: -3.22 > 6 (EBITDA TTM -120.0m / Interest Expense TTM 42.1m)

Altman Z'' -8.79

A: 0.39 (Total Current Assets 332.0m - Total Current Liabilities 124.6m) / Total Assets 525.2m
B: -2.02 (Retained Earnings -1.06b / Total Assets 525.2m)
C: -0.26 (EBIT TTM -135.8m / Avg Total Assets 522.2m)
D: -2.91 (Book Value of Equity -1.06b / Total Liabilities 363.8m)
Altman-Z'' Score: -8.79 = D

Beneish M -2.95

DSRI: 0.55 (Receivables 26.5m/25.2m, Revenue 161.3m/84.3m)
GMI: 0.79 (GM 49.98% / 39.46%)
AQI: 1.22 (AQ_t 0.07 / AQ_t-1 0.06)
SGI: 1.91 (Revenue 161.3m / 84.3m)
TATA: -0.14 (NI -177.9m - CFO -103.3m) / TA 525.2m)
Beneish M-Score: -2.95 (Cap -4..+1) = A

What is the price of RGNX shares?

As of March 06, 2026, the stock is trading at USD 8.72 with a total of 1,470,655 shares traded.
Over the past week, the price has changed by -0.34%, over one month by -15.01%, over three months by -33.74% and over the past year by +39.52%.

Is RGNX a buy, sell or hold?

Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.
  • StrongBuy: 6
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RGNX price?

Issuer Target Up/Down from current
Wallstreet Target Price 28.5 226.3%
Analysts Target Price 28.5 226.3%

RGNX Fundamental Data Overview March 02, 2026

P/S = 2.8368
P/B = 2.8313
P/EG = 0.26
Revenue TTM = 161.3m USD
EBIT TTM = -135.8m USD
EBITDA TTM = -120.0m USD
Long Term Debt = 76.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 50.8m USD (from shortTermDebt, last quarter)
Debt = 268.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 209.3m USD (from netDebt column, last quarter)
Enterprise Value = 451.6m USD (457.6m + Debt 268.1m - CCE 274.2m)
Interest Coverage Ratio = -3.22 (Ebit TTM -135.8m / Interest Expense TTM 42.1m)
EV/FCF = -4.25x (Enterprise Value 451.6m / FCF TTM -106.3m)
FCF Yield = -23.54% (FCF TTM -106.3m / Enterprise Value 451.6m)
FCF Margin = -65.88% (FCF TTM -106.3m / Revenue TTM 161.3m)
Net Margin = -110.3% (Net Income TTM -177.9m / Revenue TTM 161.3m)
Gross Margin = 49.98% ((Revenue TTM 161.3m - Cost of Revenue TTM 80.7m) / Revenue TTM)
Gross Margin QoQ = -107.9% (prev 57.33%)
Tobins Q-Ratio = 0.86 (Enterprise Value 451.6m / Total Assets 525.2m)
Interest Expense / Debt = 4.91% (Interest Expense 13.2m / Debt 268.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -107.3m (EBIT -135.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.66 (Total Current Assets 332.0m / Total Current Liabilities 124.6m)
Debt / Equity = 1.66 (Debt 268.1m / totalStockholderEquity, last quarter 161.5m)
Debt / EBITDA = -1.74 (negative EBITDA) (Net Debt 209.3m / EBITDA -120.0m)
Debt / FCF = -1.97 (negative FCF - burning cash) (Net Debt 209.3m / FCF TTM -106.3m)
Total Stockholder Equity = 227.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.07% (Net Income -177.9m / Total Assets 525.2m)
RoE = -78.29% (Net Income TTM -177.9m / Total Stockholder Equity 227.2m)
RoCE = -44.70% (EBIT -135.8m / Capital Employed (Equity 227.2m + L.T.Debt 76.5m))
RoIC = -47.20% (negative operating profit) (NOPAT -107.3m / Invested Capital 227.2m)
WACC = 10.65% (E(457.6m)/V(725.8m) * Re(14.61%) + D(268.1m)/V(725.8m) * Rd(4.91%) * (1-Tc(0.21)))
Discount Rate = 14.61% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.38%
[DCF] Fair Price = unknown (Cash Flow -106.3m)
EPS Correlation: 66.75 | EPS CAGR: 102.0% | SUE: 3.14 | # QB: 1
Revenue Correlation: -26.72 | Revenue CAGR: -49.95% | SUE: 0.66 | # QB: 0
EPS next Year (2026-12-31): EPS=-2.18 | Chg7d=-0.111 | Chg30d=-0.131 | Revisions Net=-1 | Growth EPS=+34.0% | Growth Revenue=+39.4%

Additional Sources for RGNX Stock

Fund Manager Positions: Dataroma | Stockcircle